• Pediatric Obesity
• Central Institutional Review Boards
• Stem Cell Research
• Medicare Coverage of DXA Bone Density Testing in Men
• Endocrine-Disrupting Chemicals
• Bioequivalence of Sodium Levothyroxine
• Steroid Abuse
• Research Funding
• Access to Affordable and Adequate Diabetes Supplies
• Monitoring and Reporting Drug Shortages
• Bioidentical Hormones
• Pay-for-Performance
• Clinical Trial Registries 
  

Other Society Statements

• Risk of Pancreatitis Associated with Certain Diabetes Medications
  
  
• Medicare Approves Payment for Care Coordination Services
  
  
• The Endocrine Society Statement to Physicians on HRT Recommendations
  
  
• Joint Statment: The Experts Do Agree About Hormone Therapy
  
  
• Society Statement on Bisphosphonate Use for Treatment of Osteoporosis
  
  
• Society Evaluates Benefits of Bariatric Surgery and Diabetes
  
  
• Endocrine Society Clarifies FDA Review of Statin Health Effects
  
  
• Endocrine Society Statement Recommends Individualization of BMD Testing Frequency
  
  
• Statement on the Suspension of Sales of Pioglitazone in Europe
  
  
• Joint Statement on Radiation Risks to Health
  
  
• Society Response to ACP Guidelines on Intensive Insulin Therapy
  
  
• Society Response to ASBMR Report on Bisphosphonate Therapy and Atypical Femur Fractures
  
  
• Congressional Sign-On Letter to Reinstate Consultation Codes
  
  
• Endocrine Society Statement on FDA’s Avandia Ruling
  
  
• FDA Advisory Committee Decision on Avandia
  
  
• Presentations from FDA Advisory Committee hearings on Avandia
  
  
• Joint Statement on Potential Cardiovascular Risks Associated with Rosiglitazone
  
  
• Joint Statement on Radioactive Precautions Following Radioactive Iodine Therapy
  
  
• Comments to CMS on EHR Meaningful Use
  
  
• Study Findings Related to the Treatment of Hypertension in Patients with Diabetes
  
  
• Society Statement on Long-Term Use of Bisphosphonates
  
  
• The Endocrine Society Statement in Response to the Senate Finance Committee Report on Avandia
  
  
• Society Recommends Against Altering Blood Glucose Control Goals
  
  
• The Endocrine Society Statement on the Use of A1C for Diabetes Diagnosis
  
  
• Lantus (Insulin Glargine) Statement for Patients 
  
  
• Statement for Providers on Potential Association of Insulin Glargine with Malignancy
  
  
• Guiding Principles for Health Reform
  
  
• The Endocrine Society Statement to Providers on the Report Published in the New England Journal of Medicine on NICE-SUGAR
  
  
• The Endocrine Society Statement on ACCORD Trial
  
  
• Joint Statement on Levothyroxine and Thyroxine
  
  
• Statement to Providers on the Report Published in the New England Journal of Medicine on Avandia
  
  
• Summary of Medicare Reform Legislation

Position Statements Under Review

Click here to view new position statement currently open for review.